Sodium glucose transporter 2 (SGLT2) inhibition with empagliflozin improves cardiac diastolic function in a female rodent model of diabetes

Sodium glucose transporter 2 (SGLT2) inhibition with empagliflozin improves cardiac diastolic function in a female rodent model of diabetes

Item
http://www.wikidata.org/entity/Q37586729
New Antihyperglycemic Drugs and Heart Failure: Synopsis of Basic and Clinical Data.Sodium Glucose Cotransporter-2 Inhibition in Heart Failure: Potential Mechanisms, Clinical Applications, and Summary of Clinical Trials.Direct cardiovascular impact of SGLT2 inhibitors: mechanisms and effects.Mechanistic Insights of Empagliflozin-Mediated Cardiac Benefits: Nearing the Starting Line : Editorial to: "Empagliflozin Improves Left Ventricular Diastolic Dysfunction in a Genetic Model of Type 2 Diabetes" by N. Hammoudi et al.Influence of apocynin on cardiac remodeling in rats with streptozotocin-induced diabetes mellitus.Empagliflozin Limits Myocardial Infarction in Vivo and Cell Death in Vitro: Role of STAT3, Mitochondria, and Redox Aspects.Un-sweetening the Heart: Possible pleiotropic effects of SGLT2 inhibitors on cardio and cerebrovascular alterations in resistant hypertensive subjects.Cardiac effects of SGLT2 inhibitors: the sodium hypothesis.Empagliflozin influences blood viscosity and wall shear stress in subjects with type 2 diabetes mellitus compared with incretin-based therapy.Circulating metabolites of strawberry mediate reductions in vascular inflammation and endothelial dysfunction in db/db mice.Mechanisms of Aerobic Exercise Impairment in Diabetes: A Narrative Review.Empagliflozin normalizes the size and number of mitochondria and prevents reduction in mitochondrial size after myocardial infarction in diabetic hearts.Dual inhibition of sodium–glucose linked cotransporters 1 and 2 exacerbates cardiac dysfunction following experimental myocardial infarction.Association between sodium glucose co-transporter 2 inhibitors and a reduced risk of heart failure in patients with type 2 diabetes mellitus: a real-world nationwide population-based cohort study.Effects of oral antidiabetic drugs on left ventricular mass in patients with type 2 diabetes mellitus: a network meta-analysisDiabetic Cardiomyopathy: Current and Future Therapies. Beyond Glycemic ControlA Direct Comparison of IV and ICV Delivery Methods for Gene Replacement Therapy in a Mouse Model of SMARD1
P2860

Sodium glucose transporter 2 (SGLT2) inhibition with empagliflozin improves cardiac diastolic function in a female rodent model of diabetes

Item
http://www.wikidata.org/entity/Q37586729
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 13 January 2017
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Sodium glucose transporter 2 ( ...... emale rodent model of diabetes
@en
Sodium glucose transporter 2
@nl
type
label
Sodium glucose transporter 2 ( ...... emale rodent model of diabetes
@en
Sodium glucose transporter 2
@nl
prefLabel
Sodium glucose transporter 2 ( ...... emale rodent model of diabetes
@en
Sodium glucose transporter 2
@nl
P1433
P1476
P2093
P2860
P2888
P304
P31
P356
P407
P433
P478
P50
P577
P6179
P698
P921
P932
P356
P1433
P1476
Sodium glucose transporter 2 ( ...... emale rodent model of diabetes
@en
P2093
P2860
P2888
P304
P31
P356
P407
P433
P478
P50
P577
P6179
P698
P921
P932